ERBB2 and breast carcinoma: Minimal socioeconomic disparities in metastatic compared with early-stage trastuzumab receipt may reflect first licensing in metastatic HER2+ disease in England in 2002 (access widened to early-stage breast cancer in 2006; refs. 59, 60).